Din FV, Theodoratou E, Farrington SM et al.
University of Edinburgh, Edinburgh, UK.
 Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer.
Coghill AE, Newcomb PA, Campbell PT et al.
Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Editor’s note: Aspirin is currently recommended to reduce the incidence of cardiovascular events in patients with risk factors for cardiovascular disease. However, it is well known that the risks of aspirin (e.g. gastrointestinal bleeding) may outweigh its benefits. A recent review of randomized clinical trials showed that daily aspirin reduces the mortality rates of several common cancers, including colorectal cancer (CRC), but there is not yet agreement on its recommended daily dosage or treatment duration in these settings (Lancet 2011;377:31–41).